Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
AGIO is in the long-term down -59% below S&P in 7 years.
Description: Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
|Shares Outstanding||EPS||-6||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||306.63%||Sales Growth - Q/Q||133.68%||P/E||-8.63|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-9.74%||ROE||-10.83%||ROI|
|Current Ratio||10.01||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||-51.61%||Net Profit Margin||-50.7%||Dividend Payout Ratio|
|Cash From Financing Activities||1.82 M||Cash From Investing Activities||44.99 M||Cash From Operating Activities||-25.59 M||Gross Profit|
|Net Profit||-4.96 M||Operating Profit||-5.2 M||Total Assets||474.34 M||Total Current Assets||364.14 M|
|Total Current Liabilities||36.38 M||Total Debt||Total Liabilities||47.52 M||Total Revenue||34.2 M|
|High 52 week||75.11||Low 52 week||42.73||Last close||62.35||Last change||5.93%|
|RSI||68.62||Average true range||2.74||Beta||1.94||Volume||828.59 K|
|Simple moving average 20 days||13.04%||Simple moving average 50 days||18.89%||Simple moving average 200 days||3.15%|
|Performance Week||5.16%||Performance Month||20.07%||Performance Quart||-5.23%||Performance Half||4.56%|
|Performance Year||26.83%||Performance Year-to-date||35.22%||Volatility daily||2.87%||Volatility weekly||6.41%|
|Volatility monthly||13.13%||Volatility yearly||45.49%||Relative Volume||130.51%||Average Volume||563.62 K|
|New High||New Low|
2019-11-17 08:42:54 | The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
2019-11-14 07:11:15 | 3 ‘Strong Buy’ Stocks to Buy on Weakness
2019-11-07 21:17:50 | Agios Announces Pricing of $256 Million Public Offering of Common Stock
2019-11-06 16:01:00 | Agios Announces Proposed Offering of Common Stock
2019-11-04 21:49:26 | Edited Transcript of AGIO earnings conference call or presentation 31-Oct-19 12:00pm GMT
2019-11-01 12:07:04 | Agios' AGIO Q3 Loss Narrower Than Expected, Revenues Miss
2019-10-31 08:55:12 | Agios Pharmaceuticals AGIO Reports Q3 Loss, Misses Revenue Estimates
2019-10-31 07:00:05 | Agios Reports Business Highlights and Third Quarter 2019 Financial Results
2019-10-31 06:00:00 | Agios Pharmaceuticals, Inc. to Host Earnings Call
2019-10-30 19:22:19 | Agios Pharmaceuticals Inc AGIO Is Burning These Hedge Funds
2019-10-09 07:00:00 | Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference
2019-10-02 12:00:41 | 3 Pharma Stocks at Risk for Downgrades
2019-10-02 11:36:03 | Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study
2019-09-30 10:30:00 | Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival PFS Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients
2019-09-30 06:30:00 | Biotech IPOs Are Risky Business. Here’s How to Do a Deal Right.
2019-09-04 17:00:00 | Agios Announces Publication of Data for Mitapivat from Core and Extension Phases of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency in the New England Journal of Medicine
2019-08-31 09:32:01 | Agios Pharmaceuticals AGIO Down 11.2% Since Last Earnings Report: Can It Rebound?
2019-08-15 10:30:02 | Agios Rides High on Tibsovo Sales Amid Acute Competition
2019-08-05 23:15:28 | Agios Pharmaceuticals Inc AGIO Q2 2019 Earnings Call Transcript
2019-08-03 17:13:02 | Edited Transcript of AGIO earnings conference call or presentation 1-Aug-19 12:00pm GMT
2019-08-01 12:02:04 | Agios' AGIO Loss Widens in Q2, Tibsovo Drives Sales
2019-08-01 08:55:12 | Agios Pharmaceuticals AGIO Reports Q2 Loss, Tops Revenue Estimates
2019-08-01 07:00:00 | Agios Reports Business Highlights and Second Quarter 2019 Financial Results
2019-07-16 08:04:56 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-06-18 08:40:12 | Agios AGIO Catches Eye: Stock Jumps 5.4%
2019-06-18 08:06:00 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-06-17 09:59:49 | Volatility 101: Should Agios Pharmaceuticals NASDAQ:AGIO Shares Have Dropped 50%?
2019-06-14 18:28:21 | Is Agios Pharmaceuticals Inc AGIO Going to Burn These Hedge Funds?
2019-06-13 08:02:28 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-06-11 08:03:03 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-06-06 09:17:39 | Life sciences VC firm Third Rock raises $770M in its largest round ever
2019-06-04 08:04:31 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-06-03 08:00:00 | Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® ivosidenib in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia AML Not Eligible for Intensive Chemotherapy
2019-06-01 09:31:01 | Agios Pharmaceuticals AGIO Down 8% Since Last Earnings Report: Can It Rebound?
2019-06-01 08:02:30 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.